Additionally, pharmacologic GSK3β inhibition by SB216763 promotes accumulation of N1-ICD and leukemic cell viability, suggesting that GSK3β is detrimental for CLL cell survival. Here, GSK3B is linked to B-cell chronic lymphocytic leukemia.